Document
false0000200406 0000200406 2020-04-14 2020-04-14 0000200406 jnj:A0.250NotesDue2022Member 2020-04-14 2020-04-14 0000200406 jnj:A1.650NotesDue2035Member 2020-04-14 2020-04-14 0000200406 jnj:A1.150NotesDue2028Member 2020-04-14 2020-04-14 0000200406 jnj:A0.650NotesDue2024Member 2020-04-14 2020-04-14 0000200406 jnj:A5.50NotesDue2024Member 2020-04-14 2020-04-14 0000200406 us-gaap:CommonStockMember 2020-04-14 2020-04-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): 
April 14, 2020
Johnson & Johnson
 (Exact name of registrant as specified in its charter)
  
New Jersey
1-3215
22-1024240
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
(Address of Principal Executive Offices)
 (Zip Code) 
Registrant's telephone number, including area code:
732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
               CFR 240.14d-2(b)) 
            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
               CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $1.00
JNJ
New York Stock Exchange
0.250% Notes Due January 2022
JNJ
New York Stock Exchange
0.650% Notes Due May 2024
JNJ
New York Stock Exchange
5.50% Notes Due November 2024
JNJ
New York Stock Exchange
1.150% Notes Due November 2028
JNJ
New York Stock Exchange
1.650% Notes Due May 2035
JNJ
New York Stock Exchange
 
 

 



Item 2.02                      Results of Operations and Financial Condition
 
On April 14, 2020, Johnson & Johnson issued the attached press release announcing its sales and earnings for the first quarter ended March 29, 2020.
 
Item 9.01            Financial Statements and Exhibits

(d)     Exhibits. 
 
Exhibit No.
 
Description of Exhibit
 
Press Release dated April 14, 2020 for the period ended March 29, 2020
 
Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the first quarter

104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
 
 




 
 
 


 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Johnson & Johnson
 
 
 
 
 (Registrant)
 
 
 
 
Date: 
April 14, 2020
By:
/s/ Robert J. Decker, Jr.
 
 
 
 
Robert J. Decker, Jr.
Controller
(Principal Accounting Officer)
 



Exhibit


Exhibit 99.1

JOHNSON & JOHNSON REPORTS 2020 FIRST-QUARTER RESULTS:
Sales of $20.7 Billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated negative impact of the COVID-19 pandemic
EPS of $2.17 increased 56.1%; adjusted EPS of $2.30 increased 9.5%*
Dividend increase of 6.3% announced
Long term fundamentals remain intact; 2020 Guidance lowered to reflect COVID-19 impact and related investments

New Brunswick, N.J. (April 14, 2020) - Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share.

“With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “Johnson & Johnson is built for times like this, and we are leveraging our scientific expertise, operational scale and financial strength in the effort to advance the work on our lead COVID-19 vaccine candidate. We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use.”

Mr. Gorsky continued, “I am both proud and amazed at the level of dedication that I have witnessed from our more than 132,000 employees as we have focused on delivering on our commitments and responsibilities to the patients and consumers we serve. Our strong performance in the first quarter reflects the efforts of our teams around the world and the sustainability of our business model. Today, our Board of Directors approved an increase in our quarterly dividend for the 58th consecutive year, underscoring our commitment to delivering value for our shareholders and the confidence we have in our business now and in the future.”
   
OVERALL FINANCIAL RESULTS:
https://cdn.kscope.io/6c674361a66a278ba7af987712309d25-q1chart1.jpg
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items






REGIONAL SALES RESULTS:


https://cdn.kscope.io/6c674361a66a278ba7af987712309d25-regionalsales005.jpg

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded


SEGMENT SALES RESULTS:

https://cdn.kscope.io/6c674361a66a278ba7af987712309d25-a2020q1segments.jpg
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded





  
SEGMENT COMMENTARY:

Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 11.0%* driven primarily by over-the-counter products including TYLENOL and MOTRIN analgesics; upper respiratory products including ZYRTEC; digestive health products and ZARBEE’S NATURALS. Other contributors to growth were LISTERINE mouthwash in oral care products; NEUTROGENA and AVEENO in skin health/beauty products, as well as STAYFREE and o.b. in international women’s health. Consumer Health results across the majority of franchises were positively impacted by the increased demand related to the COVID-19 pandemic.

Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 10.2%* driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, OPSUMIT (macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This growth was partially offset by biosimilar and generic competition, with declines primarily in international VELCADE (bortezomib), a proteasome inhibitor for the treatment of multiple myeloma, REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and PROCRIT (epoetin alfa), a treatment for chemotherapy-induced anemia and patients with chronic kidney disease.

Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by 4.8%* driven by the estimated net negative impact of the COVID-19 pandemic and the associated deferral of medical procedures to our Surgery, Orthopaedics, Interventional Solutions and Vision businesses.

 





NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the Company’s website at news releases.
Regulatory
Approvals

ERLEADA (apalutamide) - European Commission (EC) Approves Expanded Use for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
(press release)
STELARA (ustekinumab) - EC Approves Expanded Use for Treatment of Pediatric Patients With Moderate To Severe Plaque Psoriasis

(press release)
Regulatory
Submissions
Ponesimod - Submission of New Drug Applications to the U.S. Food and Drug Administration (FDA) and European Marketing Authorization for Treatment of Adults with Relapsing Multiple Sclerosis

(press release)
DARZALEX (daratumumab) - Submission to U.S. FDA for Combination with carfilzomib and dexamethasone (DKd) For Patients with Relapsed/Refractory Multiple Myeloma
 
Other
Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use; Announced

(press release)
XARELTO (rivaroxaban) -Landmark Phase 3 VOYAGER PAD Study of XARELTO Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
(press release)
Rilpivirine And Cabotegravir Results of Phase 3 FLARE Study Demonstrate the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen through 96 Weeks
(press release)
Rilpivirine and Cabotegravir 48-week Results of Phase 3b ATLAS-2M Study Demonstrate the Safety and Efficacy of Long-Acting Injectable HIV Treatment Administered Every Two Months
(press release)
JNJ-6372 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Non-Small Cell Lung Cancer
(press release)
RPGR Gene Therapy Granted European Medicines Agency PRIME and Advanced Therapy Medicinal Product Designations for X-Linked Retinitis Pigmentosa
(press release)
HEARTLINE launched, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone® App and Apple Watch® Can Help Reduce the Risk of Stroke1

(press release)
1 iPhone and Apple Watch are trademarks of their respective owners






FULL-YEAR 2020 GUIDANCE:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
The impact of COVID-19, inclusive of the related investments the Company is making to combat the pandemic, is included in the guidance below.


 
April 2020
January 2020
($ in Billions, except EPS)    
Adjusted Operational Sales1,2
Change vs. Prior Year
(3.0%) - 0.5%
5.0% - 6.0%
Operational Sales2
Change vs. Prior Year
$79.2 to $82.2
(3.5%) - 0.0%
$85.8 to $86.6
4.5% - 5.5%
Estimated Reported Sales3
Change vs. Prior Year
$77.5 to $80.5
(5.5%) - (2.0%)
$85.4 to $86.2
4.0% - 5.0%
 
 
 
Adjusted Operational EPS (Diluted)2,4
Change vs. Prior Year
$7.65 to $80.5
(11.9%) - (7.3%)
$9.00 to $9.15
3.7% - 5.4%
Adjusted EPS (Diluted)3,4
Change vs. Prior Year
$7.50 to $7.90
(13.6%) - (9.0%)
$8.95 to $9.10
3.1% - 4.8%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: April 2020 = $1.09 Euro Average Rate: January 2020 = $1.11 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the Company's website at events-and-presentations.

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach





and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
 
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the Company's website at quarterly-results.

Copies of the financial schedules accompanying this earnings release are available on the Company’s website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the Company's website at quarterly-results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.






 

Press Contacts:    Investor Contacts:

Cristal Downing        Christopher DelOrefice        Lisa Romanko
(732) 524-3283        (732) 524-2955            (732) 524-2034
(908) 616-8833 (M)

    


Exhibit
Exhibit 99.2


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FIRST QUARTER
 
 
 
 
 
Percent Change
 
2020
 
2019
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 $ 10,699
 
  10,129
 
   5.6

%
            5.6

 

 
 
 
 
 
 
 
 
 
 
Europe
      4,827
 
    4,609
 
4.7

 
            7.5

 
(2.8
)
Western Hemisphere excluding U.S.
      1,502
 
    1,503
 
(0.1
)
 
            8.5

 
(8.6
)
Asia-Pacific, Africa
      3,663
 
    3,780
 
(3.1
)
 
(1.9
)
 
(1.2
)
International
      9,992
 
    9,892
 
   1.0

 
            4.0

 
(3.0
)
 
 
 
 
 
  
 
  
 
  
Worldwide
 $ 20,691
 
  20,021
 
   3.3

%
            4.8

 
(1.5
)
 
 
 
  
 
  
 
  
 
  
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.














Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FIRST QUARTER
 
 
 
 
 
 Percent Change
 
2020
 
2019
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer Health
 
 
 
 
 
 
 
 
 
    U.S.
 $ 1,740
 
    1,438
 
21.0

%
             21.0
 

    International
      1,885
 
    1,880
 
0.3

 
               3.9
 
(3.6
)
 
      3,625
   
    3,318
 
9.2

 
             11.3
 
(2.1
)
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
      6,061
 
    5,582
 
8.6

 
               8.6
 

    International
      5,073
 
    4,662
 
8.8

 
             12.0
 
(3.2
)
 
    11,134
   
  10,244
 
8.7

 
             10.1
 
(1.4
)
 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
    U.S.
      2,898
   
    3,109
 
(6.8
)
 
             (6.8)
 

    International
      3,034
 
    3,350
 
(9.4
)
 
             (6.9)
 
(2.5
)
 
      5,932
   
    6,459
 
(8.2
)
 
             (6.9)
 
(1.3
)
 
 
 
 
 
 
 
 
 
 
U.S.
    10,699
 
  10,129
 
5.6

 
               5.6
 

International
      9,992
 
    9,892
 
1.0

 
               4.0
 
(3.0
)
Worldwide
 $ 20,691
 
  20,021
 
3.3

%
               4.8
 
(1.5
)
 
   
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 

Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
FIRST QUARTER
 
 
 
 
 
 
 
 
 
 
 
2020
 
2019
 
Percent

 
 
 
Percent
 
 
 
Percent
 
Increase

 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)

Sales to customers
 $ 20,691

 
     100.0

 
 $ 20,021

 
     100.0

 
3.3

Cost of products sold
      7,062

 
       34.1

 
      6,615

 
       33.0

 
6.8

Gross Profit
    13,629

 
65.9

 
    13,406

 
67.0

 
1.7

Selling, marketing and administrative expenses
      5,203

 
       25.1

 
      5,219

 
       26.1

 
(0.3
)
Research and development expense
      2,580

 
       12.5

 
      2,858

 
       14.3

 
(9.7
)
In-process research and development

 

 
         890

 
         4.4

 
 
Interest (income) expense, net
(42
)
 
(0.2
)
 
             3

 
         0.0

 
 
Other (income) expense, net
(679
)
 
(3.3
)
 
(22
)
 
(0.1
)
 
 
Restructuring
           58

 
         0.3

 
           36

 
         0.2

 
 
Earnings before provision for taxes on income
      6,509

 
       31.5

 
      4,422

 
       22.1

 
47.2

Provision for taxes on income
         713

 
         3.5

 
         673

 
         3.4

 
5.9

Net earnings
      5,796

 
       28.0

 
      3,749

 
       18.7

 
54.6

 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 2.17

 
 
 
 $ 1.39

 
 
 
56.1

 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,671.0

 
 
 
2,698.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
11.0

%
 
 
15.2

%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 7,244

 
35.0

 
 $ 6,867

 
34.3

 
5.5

Net earnings
 $ 6,154

 
29.7

 
 $ 5,661

 
28.3

 
8.7

Net earnings per share (Diluted)
 $ 2.30

 
 
 
 $ 2.10

 
 
 
9.5

Effective tax rate
15.0

%
 
 
17.6

%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.







Johnson & Johnson and Subsidiaries
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
First Quarter
 
(Dollars in Millions Except Per Share Data)
 
2020
 
2019
 
Net Earnings, after tax- as reported
 
$5,796

 
$3,749

 
 
 
 
 
 
 
Pre-tax Adjustments
 
 
 
 
 
Intangible Asset Amortization expense
 
1,118

 
1,130

 
Litigation expense
 
120

 
423

 
IPR&D
 

 
890

 
Restructuring related
 
118

 
90

 
Acquisition and Integration related 1
 
(962
)
 
67

 
Unrealized (gains)/losses on securities
 
327

 
(158
)
 
Medical Device Regulation 2
 
14

 

 
Other
 

 
3

 
 
 
 
 
 
 
Tax Adjustments
 
 
 
 
 
Tax impact on special item adjustments 3
 
(267
)
 
(533
)
 
Tax legislation and related impacts
 
(110
)
 

 
Adjusted Net Earnings, after tax
 
$6,154

 
$5,661

 
Average shares outstanding (Diluted)
 
2,671.0

 
2,698.8

 
Adjusted net earnings per share (Diluted)
 
$2.30

 
$2.10

 
Operational adjusted net earnings per share (Diluted)
 
$2.32

 
 
 
 
 
 
 
 
 
Notes:
 
 
 
 
 
1 Acquisition and integration related costs for the first quarter of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
 
2 European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
 
3 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.







Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted Operational Sales Growth (A)
 FIRST QUARTER 2020 ACTUAL vs. 2019 ACTUAL
 
 Segments
 
 
 Consumer Health
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 WW As Reported
 
9.2%
 
8.7%
 
(8.2)%
 
3.3%
 U.S.
 
21.0%
 
8.6%
 
(6.8)%
 
5.6%
 International
 
0.3%
 
8.8%
 
(9.4)%
 
1.0%
 
 
 
 
 
 
 
 
 
 WW Currency
 
(2.1)
 
(1.4)
 
(1.3)
 
(1.5)
 U.S.
 
 
 
 
 International
 
(3.6)
 
(3.2)
 
(2.5)
 
(3.0)
 
 
 
 
 
 
 
 
 
 WW Operational
 
11.3%
 
10.1%
 
(6.9)%
 
4.8%
 U.S.
 
21.0%
 
8.6%
 
(6.8)%
 
5.6%
 International
 
3.9%
 
12.0%
 
(6.9)%
 
4.0%
 
 
 
 
 
 
 
 
 
Skin Health / Beauty
 
 
 
 
 
 
 
 
Dr. Ci Labo - Japan
 
(0.4)
 
 
 
 
 
(0.1)
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(0.7)
 
 
 
 
 
(0.1)
 
 
 
 
 
 
 
 
 
General Surgery
 
 
 
 
 
 
 
 
Advanced Sterilization Products
 
 
 
 
 
2.1
 
0.8
 U.S.
 
 
 
 
 
2.7
 
0.9
 International
 
 
 
 
 
1.6
 
0.6
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
Baby Center
 
0.3
 
 
 
 
 
0.0
 U.S.
 
0.8
 
 
 
 
 
0.1
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
(0.2)
 
0.1
 
(0.1)
 
0.0
 U.S.
 
0.0
 
0.1
 
(0.2)
 
0.0
 International
 
(0.3)
 
0.0
 
0.1
 
0.0
 
 
 
 
 
 
 
 
 
WW Adjusted Operational
 
11.0%
 
10.2%
 
(4.8)%
 
5.6%
 U.S.
 
21.7%
 
8.7%
 
(4.3)%
 
6.7%
 International
 
2.8%
 
12.0%
 
(5.3)%
 
4.5%
 
 
 
 
 
 
 
 
 
Note: Percentages are based on actual, non-rounded figures and may not sum
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.









Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency

CONSUMER HEALTH SEGMENT (2) (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
92

 
87

 
6.7
 %
6.7
 %
 %
Intl
 
 
269

 
307

 
(12.4
)
(8.2
)
(4.2
)
WW
 
 
361

 
394

 
(8.2
)
(4.9
)
(3.3
)
 
 
 
 
 
 
 
 
 
 
SKIN HEALTH / BEAUTY (4)
 
 
 
 
 
 
 
 
 
US
 
 
659

 
588

 
12.1

12.1


Intl
 
 
458

 
502

 
(8.8
)
(6.5
)
(2.3
)
WW
 
 
1,117

 
1,090

 
2.5

3.5

(1.0
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
176

 
151

 
16.2

16.2


Intl
 
 
219

 
216

 
1.5

5.3

(3.8
)
WW
 
 
395

 
367

 
7.6

9.8

(2.2
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
689

 
507

 
35.9

35.9


Intl
 
 
659

 
580

 
13.7

17.0

(3.3
)
WW
 
 
1,348

 
1,087

 
24.1

25.8

(1.7
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
4

 
3

 
32.0

32.0


Intl
 
 
228

 
222

 
2.5

8.9

(6.4
)
WW
 
 
232

 
225

 
2.9

9.2

(6.3
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE / OTHER
 
 
 
 
 
 
 
 
 
US
 
 
119

 
102

 
17.0

17.0


Intl
 
 
52

 
53

 
(1.2
)
1.9

(3.1
)
WW
 
 
171

 
155

 
10.7

11.8

(1.1
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
1,740

 
1,438

 
21.0

21.0


Intl
 
 
1,885

 
1,880

 
0.3

3.9

(3.6
)
WW
 
$
3,625

 
3,318

 
9.2
 %
11.3
 %
(2.1
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 






Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
2,410

 
2,163

 
11.4
 %
11.4
 %
 %
Intl
 
 
1,228

 
1,088

 
12.8

16.3

(3.5
)
WW
 
 
3,638

 
3,251

 
11.9

13.1

(1.2
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
625

 
774
 
(19.3
)
(19.3
)

     US Exports (5)
 
 
110

 
76

 
44.3

44.3


     Intl
 
 
256

 
252

 
1.5

5.2

(3.7
)
     WW
 
 
990

 
1,102

 
(10.2
)
(9.3
)
(0.9
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
272

 
263

 
3.4

3.4


     Intl
 
 
258

 
261

 
(1.2
)
2.6

(3.8
)
     WW
 
 
529

 
524

 
1.1

3.0

(1.9
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
1,217

 
882

 
37.9

37.9


     Intl
 
 
603

 
523

 
15.2

18.3

(3.1
)
     WW
 
 
1,819

 
1,405

 
29.5

30.6

(1.1
)
     TREMFYA
 
 
 
 
 
 
 
 
 
     US
 
 
187

 
168

 
11.5

11.5


     Intl
 
 
109

 
49

 
*

*

*

     WW
 
 
296

 
217

 
36.4

37.3

(0.9
)
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 

 

 



     Intl
 
 
3

 
3

 
(6.9
)
(5.6
)
(1.3
)
     WW
 
 
3

 
3

 
(6.9
)
(5.6
)
(1.3
)
 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
436

 
357

 
22.3

22.3


Intl
 
 
483

 
489

 
(1.2
)
2.7

(3.9
)
WW
 
 
920

 
846

 
8.7

11.0

(2.3
)
     EDURANT / rilpivirine
 
 
 
 
 
 
 
 
 
     US
 
 
12

 
12

 
0.6

0.6


     Intl
 
 
212

 
199

 
6.4

9.2

(2.8
)
     WW
 
 
224

 
211

 
6.1

8.7

(2.6
)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
 
 
 
 
 
 
     US
 
 
396

 
315

 
25.5

25.5


     Intl
 
 
184

 
208

 
(11.6
)
(6.4
)
(5.2
)
     WW
 
 
579

 
523

 
10.8

12.8

(2.0
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
29

 
30

 
(3.4
)
(3.4
)

     Intl
 
 
87

 
82

 
6.7

10.2

(3.5
)
     WW
 
 
116

 
112

 
4.0

6.6

(2.6
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
748

 
723

 
3.3
 %
3.3
 %
 %
Intl
 
 
910

 
905

 
0.5

3.0

(2.5
)
WW
 
 
1,658

 
1,629

 
1.8

3.1

(1.3
)
     CONCERTA / methylphenidate
 
 
 
 
 
 
 
 
 
     US
 
 
52

 
97

 
(46.1
)
(46.1
)

     Intl
 
 
118

 
116

 
1.5

3.6

(2.1
)
     WW
 
 
171

 
214

 
(20.1
)
(19.0
)
(1.1
)
     INVEGA SUSTENNA / XEPLION / INVEGA
 
 
 
 
 
     TRINZA / TREVICTA
 
 
 
 
 
 
 
 
 
     US
 
 
544

 
483

 
12.6

12.6


     Intl
 
 
339

 
307

 
10.3

13.2

(2.9
)
     WW
 
 
883

 
790

 
11.7

12.9

(1.2
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
76

 
77

 
(0.3
)
(0.3
)

     Intl
 
 
94

 
102

 
(8.7
)
(5.9
)
(2.8
)
     WW
 
 
170

 
179

 
(5.1
)
(3.5
)
(1.6
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
75

 
66

 
12.5

12.5


     Intl
 
 
360

 
379

 
(5.1
)
(3.1
)
(2.0
)
     WW
 
 
435

 
446

 
(2.5
)
(0.8
)
(1.7
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
1,175

 
962

 
22.1

22.1


Intl
 
 
1,839

 
1,556

 
18.2

21.7

(3.5
)
WW
 
 
3,013

 
2,518

 
19.7

21.8

(2.1
)
     DARZALEX
 
 
 
 
 
 
 
 
 
     US
 
 
463

 
352

 
31.8

31.8


     Intl
 
 
474

 
277

 
70.9

76.8

(5.9
)
     WW
 
 
937

 
629

 
49.0

51.6

(2.6
)
     ERLEADA (6)
 
 
 
 
 
 
 
 
 
     US
 
 
119

 
58

 
*

*


     Intl
 
 
24

 
3

 
*

*

*

     WW
 
 
143

 
61

 
*

*

*

     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
432

 
349

 
23.9

23.9


     Intl
 
 
599

 
435

 
37.8

42.3

(4.5
)
     WW
 
 
1,031

 
784

 
31.6

34.1

(2.5
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 

 

 



     Intl
 
 
108

 
263

 
(59.0
)
(58.2
)
(0.8
)
     WW
 
 
108

 
263

 
(59.0
)
(58.2
)
(0.8
)
     ZYTIGA / abiraterone acetate
 
 
 
 
 
 
 
 
 
     US
 
 
139

 
185

 
(25.2
)
(25.2
)

     Intl
 
 
552

 
494

 
11.7

14.3

(2.6
)
     WW
 
 
690

 
679

 
1.6

3.5

(1.9
)
     OTHER ONCOLOGY (6)
 
 
 
 
 
 
 
 
 
     US
 
 
22

 
18

 
20.1

20.1


     Intl
 
 
82

 
84

 
(2.7
)
0.6

(3.3
)
     WW
 
 
104

 
102

 
1.3

4.1

(2.8
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
US
 
$
486

 
430

 
13.0
 %
13.0
 %
 %
Intl
 
 
260

 
226

 
14.9

17.8

(2.9
)
WW
 
 
745

 
656

 
13.7

14.7

(1.0
)
     OPSUMIT
 
 
 
 
 
 
 
 
 
     US
 
 
229

 
172

 
33.0

33.0


     Intl
 
 
160

 
133

 
20.2

23.3

(3.1
)
     WW
 
 
389

 
306

 
27.4

28.8

(1.4
)
     UPTRAVI
 
 
 
 
 
 
 
 
 
     US
 
 
212

 
176

 
20.7

20.7


     Intl
 
 
38

 
22

 
70.2

75.0

(4.8
)
     WW
 
 
250

 
198

 
26.2

26.8

(0.6
)
     OTHER PULMONARY HYPERTENSION (6)
 
 
 
 
 
 
 
     US
 
 
44

 
82

 
(45.9
)
(45.9
)

     Intl
 
 
62

 
71

 
(12.4
)
(10.7
)
(1.7
)
     WW
 
 
106

 
152

 
(30.4
)
(29.6
)
(0.8
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER
 
 
 
 
 
 
US
 
$
806

 
947

 
(14.9
)%
(14.9
)%
 %
Intl
 
 
354

 
398

 
(11.0
)
(8.7
)
(2.3
)
WW
 
 
1,160

 
1,345

 
(13.8
)
(13.1
)
(0.7
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
527

 
542

 
(2.7
)
(2.7
)

     Intl
 
 

 

 



     WW
 
 
527

 
542

 
(2.7
)
(2.7
)

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
117

 
154

 
(23.6
)
(23.6
)

     Intl
 
 
58

 
49

 
18.6

20.9

(2.3
)
     WW
 
 
175

 
202

 
(13.5
)
(12.9
)
(0.6
)
     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
76

 
148

 
(48.5
)
(48.5
)

     Intl
 
 
79

 
78

 
0.4

1.9

(1.5
)
     WW
 
 
155

 
226

 
(31.6
)
(31.0
)
(0.6
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
85

 
104

 
(18.0
)
(18.0
)

     Intl
 
 
217

 
271

 
(19.7
)
(17.1
)
(2.6
)
     WW
 
 
302

 
374

 
(19.2
)
(17.4
)
(1.8
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
6,061

 
5,582

 
8.6

8.6


Intl
 
 
5,073

 
4,662

 
8.8

12.0

(3.2
)
WW
 
$
11,134

 
10,244

 
8.7
 %
10.1
 %
(1.4
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)